Navigation Links
Brainlab Continues to Advance Global Treatment Access and Consistency in Cancer Care Centers
Date:7/25/2012

MUNICH, July 25, 2012 /PRNewswire/ -- Today Brainlab announced the inauguration of the 300th Novalis® Radiosurgery Program. The addition of another healthcare facility to the worldwide Novalis treatment, communication and collaboration network allows Brainlab to expand and build upon this distinctive and comprehensive program that the company established 15 years ago and continues to transform. These centers all share premium, standard-defining Brainlab technology, allowing for direct and consistent implementation of the same treatment protocols for radiosurgery and stereotactic body radiation therapy (SBRT).

The 300th Novalis Radiosurgery Program represents a significant milestone since Brainlab inaugurated the first Novalis Radiosurgery system at the University of California, Los Angeles (UCLA), USA. Radiosurgery has advanced significantly over the past 15 years, with much of the conversation focusing around hardware innovations. While these iterations are an important part of industry progress, changing the paradigm has been realized by advances in software and patient positioning, such as volumetric dose planning, conformal dynamic arcs and 6D patient alignment.

The Novalis Radiosurgery Program has remained a constant within the industry progression, offering a comprehensive approach that encompasses technology, best practice and leadership. Facilities can be confident that they are consistently delivering a high standard of radiosurgery and SBRT, delivered via a premium configuration of components. All 300 Novalis Radiosurgery Program facilities can share protocols without extensive hardware adaptation to their Novalis-configured linear accelerator. This uniformity has the capacity to liberate customers, allowing them to adapt and drive new treatment protocols in high quality, non-invasive1 cancer treatment.

"The Novalis Radiosurgery Program has opened doors for patients in many different ways," says David W. Andrews, MD, at Thomas Jefferson University Hospitals in Philadelphia, Pennsylvania. "The capabilities that we now have in terms of dose planning and treatment delivery are widening not only the types of cancers we can treat, but the precision with which we treat them. In the last decade, there have been significant changes in how we approach intracranial lesions. Our investment into the Novalis Radiosurgery Program has been one factor that has enabled us to realize and implement consistent, modern radiosurgery treatment protocols as well as establish an elevated standard of care."

The advanced Novalis Radiosurgery software and patient positioning ensure that each system can accurately track and treat tumors virtually anywhere in the body in as little as a single session. Novalis Radiosurgery offers a painless alternative or complement to invasive1 surgery and may deliver fewer side effects. Neurosurgeons choose Novalis Radiosurgery because the Program offers them not only a streamlined transition from surgery, but is also a viable primary treatment alternative. With the largest active installed base in radiosurgery, the Novalis Program provides patients across the globe access to what has become a benchmark in cranial radiosurgery.

"At Brainlab, our aim over the last 20 years has been unwavering; to improve the care and quality of life for as many cancer patients as possible," says Stefan Vilsmeier, founder and CEO of Brainlab. "We do this by providing clinicians access to some of the latest treatment technology, which draws upon the interconnectivity between medical devices and clinical expertise. The growing network of Novalis Radiosurgery Programs treats more patients than all other dedicated radiosurgery systems combined. Brainlab will continue to enable the consistent application of more precise treatments, benchmarked against what is Best Practice in this field, in order to treat more cancer patients and impact more lives."

About Brainlab
Brainlab develops, manufactures and markets software-driven medical technology with the aim of optimizing patient treatments. Core products revolve around less invasive image guided surgery technology, more accurate and effective radiation therapy, and integration through planning and collaboration systems that brings patient data and physicians together. www.brainlab.com

Press enquiries to:

Paula Moggio
Account Manager
D +1 323 762 2434
M +1 626 319 6919
Paula.Moggio@porternovelli.com
porternovelli.com

1  Some doctors may opt for a minimally invasive head frame depending on the specific treatment and patient.

 


'/>"/>
SOURCE Brainlab
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
2. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
5. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
8. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
9. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
10. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
11. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... -- Hutchison China MediTech (Chi-Med) (HCM) ... highly lucrative global oncology and immunology markets. HCM ... or best-in-class tyrosine kinase inhibitor (TKI) drugs, some ... HCM,s profitable Chinese healthcare business continues to benefit ... of the mid-to-late-stage pipeline during 2016-17 (including US ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
Breaking Medicine Technology:
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... With ... intervention to walk, the demand for a sustainable product to aid in the rehabilitation ... and aid in the recovery of individuals with hemiplegia due to stroke. , Ekso ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... 2016 , ... Cabot Corporation, Pfizer, and 3M are responsible ... documents and SEC filings. A jury has returned a verdict of $32.8 ... Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million in ...
Breaking Medicine News(10 mins):